The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > COMMENTARY
COMMENTARY
- COMMENTARY/Market for Osteoporosis Drugs Booms
July 9, 2007
- COMMENTARY/Pressure Mounting on Long-Listed Original Drugs
July 9, 2007
- COMMENTARY:Generic Firms Need Stronger Business Platform to Ensure Nationwide Stable Supply
June 25, 2007
- COMMENTARY/Provisional Deliveries without Agreement on Prices
June 11, 2007
- COMMENTARY/Show Road Map to the Goal - 30% Share for Generics
June 4, 2007
- COMMENTARY/Korosho to Consider Introduction of CU System
May 28, 2007
- Explosion of Shin-Etsu Chemical's Cellulose Production PlantGood Opportunity to Reconsider Raw Material Procurement System
April 30, 2007
- COMMENTARY/Japan Moves toward Affiliation with PIC/S
April 23, 2007
- COMMENTARY/India Attracts Increasing Attention of Japanese Pharmas
April 16, 2007
- COMMENTARY:Growing Market for Biopharmaceuticals
April 2, 2007
- Japanese Pharma Companies' Licensing Policy: 1 (2) Takeda Pharmaceutical Co., Ltd.
March 26, 2007
- Comentary
March 26, 2007
- Japanese Pharma Companies' Licensing Policy: 1 (1) Takeda Pharmaceutical Co., Ltd.
March 26, 2007
- Future of the Life Sciences Industries: Strategies for Success in 2015
March 19, 2007
- 3 Advantages of Gov't-Private Sector Dialogue Industry Needs to Continuously Present Proposals
February 19, 2007
- Breakthrough Pipelines of Japanese Pharma Companies Keiji Nakamura, Ph. D. Pharma Forum Institute, Kamakura 248-0026
February 12, 2007
- Present and Future of Pharmaceutical Companies in Japan -1- -Prospects for 2001 Analyzed Based on Korosho's Vision for the Pharmaceutical Industry-
January 22, 2007
- Present and Future of Pharmaceutical Companies in Japan -2- -Prospects for 2001 Analyzed Based on Korosho's Vision for the Pharmaceutical Industry-
January 22, 2007
- COMMENTARY 4 articles
December 25, 2006
- Reform Promotion Council to Propose Reference Price System Again
December 11, 2006
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…